StockNews.AISignal intelligence

Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

Browse signals
TBPHBullishEarningsnews
High materiality9/10

Zymeworks to buy Theravance Biopharma at $17 cash plus CVR; 2H2026 close

Aug 10, 2026, 8:34 AM EDT1 sourcesAI-analyzed
Why it may matterVerify against the original reporting

Acquisition at a fixed cash price typically induces near-term upside in a small-cap name; CVR adds optional upside but introduces single-event risk if the deal stalls.

AI summary

What happened, with direct paths to the underlying reporting

Theravance Biopharma disclosed a definitive agreement to be acquired by Zymeworks for $17 per share in cash plus a contingent value right (CVR). The deal is expected to close in the second half of 2026, subject to shareholder approval and standard closing conditions, while YUPELRI continues to generate collaboration revenue and the company advances its restructuring to improve cash flow. The acquisition provides near-term value to TBPH holders and preserves the core asset's monetization upside via the CVR.

  • Zymeworks to acquire Theravance Biopharma for $17 per share cash plus CVR.
  • Close expected in H2 2026, subject to Theravance shareholder approval.
  • YUPELRI collab revenue up 11% YoY to $20.7m; TBPH implied 35% share of YUPELRI net sales (~$24.7m).
  • Operating expenses down 35% YoY; 2H2026 run-rate savings targeted at $60–$70m.
  • Q2 2026: total revenue $20.7m; net loss $5.9m; cash $387.7m; no debt.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

Related signals

More source-backed signals connected by company or event